Embed

Academic

Authors

Joelle Guilhot

Joelle Guilhot (Joëlle Guilhot),Université de Poitiers,Oncology,Neuroscience,Diabetes

Edit

Joelle Guilhot (Joëlle Guilhot)

Université de Poitiers

Publications: 43 | Citations: 536

Fields: Oncology, Neuroscience, Diabetes

Collaborated with 311 co-authors from 1997 to 2011 | Cited by 2173 authors

Cumulative Annual

Sort by:

Publications (43)

BibTeX | RIS | RefWorks Download

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=56563992&selfId1=23880540&selfId2=0&maxNumber=12&query=

Journal: Leukemia , vol. 25, no. 10, pp. 1661-1664, 2011

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=49183125&selfId1=23880540&selfId2=0&maxNumber=12&query=

Journal: Leukemia Research - LEUK RES , vol. 35, no. 6, pp. 777-782, 2011

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (Citations: 20)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=49598001&selfId1=23880540&selfId2=0&maxNumber=12&query=

Journal: Lancet Oncology - LANCET ONCOL , vol. 11, no. 11, pp. 1029-1035, 2010

Prognostic value of O 6 -methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods (Citations: 14)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=32054369&selfId1=23880540&selfId2=0&maxNumber=12&query=

Journal: Journal of Neuro-oncology - J NEURO-ONCOL , vol. 97, no. 3, pp. 311-322, 2010

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase (Citations: 10)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=14098111&selfId1=23880540&selfId2=0&maxNumber=12&query=

Published in 2010.

Sort by:

Citations (536 times by 476 publications)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

Journal: Leukemia , vol. 26, no. 2, pp. 214-224, 2012

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

, , , , , , , , , , ,

Journal: Leukemia , vol. 26, no. 3, pp. 465-474, 2012

Comments

Co-authors (311)

Journals (22)

Keywords (131)

Joelle Guilhot (Joëlle Guilhot),Université de Poitiers,Oncology,Neuroscience,Diabetes

Publications (43)

BibTeX | RIS | RefWorks Download

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (Citations: 20)

Prognostic value of O 6 -methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods (Citations: 14)

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase (Citations: 10)

Citations (536 times by 476 publications)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton

Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning

Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer


	View FAQ about top research areas and Fields of study

Joelle Guilhot (Joëlle Guilhot),Université de Poitiers,Oncology,Neuroscience,Diabetes

Publications (43) BibTeX | RIS | RefWorks Download

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (Citations: 20)

Prognostic value of O 6 -methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods (Citations: 14)

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase (Citations: 10)

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy (Citations: 1)

Publications (43)

BibTeX | RIS | RefWorks Download